← All stocks

CRESCENT BIOPHARMA, INC.

CBIO Net buying
CIK 0001253689 #2943 in the set updated 17 Sep 2026
Bought (12 mo)
$30.61M
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$1.23M
$1.23M on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 7 sales
Net
+$29.39M
+$30.61M against sales at will

By person

10 insiders · 9 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Fairmount Funds Management LLC entity
Director
$30.61M (2)
+$30.61M
3,601,316
$52.22M
+159.5%
Brumm Joshua T
Chief Executive Officer
$761.07K (1) scheduled
−$761.07K
281,212
$4.08M
+4.8%
McNeill Jonathan
President and COO
$369.68K (1) scheduled
−$369.68K
139,158
$2.02M
+3.7%
Pinkas Jan
Chief Scientific Officer
$23.17K (1) scheduled
−$23.17K
22,239
$322.47K
+2,080%
Im Ellie Eunkyung
Chief Medical Officer
$21.93K (1) scheduled
−$21.93K
22,069
$320.00K
+1,009%
Bispham Barbara Harlin
See Remarks
$21.91K (1) scheduled
−$21.91K
19,330
$280.29K
+809.2%
Scalzo Richard William
Chief Financial Officer
$20.00K (1) scheduled
−$20.00K
20,298
$294.32K
+921.0%
Lynch Ryan
See Remarks
$8.37K (1) scheduled
−$8.37K
13,871
$201.13K
+608.4%
BVF PARTNERS L P/IL entity
10% owner
62,383
$904.55K
Doughty Christopher Grant
Chief Business Officer
62,194
$901.81K
+57.5%

No percentages here. This company's share count has moved by a factor of 4.6 over the window, from 13,892,516 to 64,532,091 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 24
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 3
Sales on a Rule 10b5-1 plan 7
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 197,365
History held since 4 Oct 2016